SCHEMBL6802330

SCHEMBL6802330

CN(CC(N)=O)C12CCCC(CC1)C2

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801113 0.79 HSD11B1 (0.31)
SCHEMBL7482047 0.75 ALDH1A1 (0.30)
SCHEMBL6802461 0.75 MAPT (0.32)
SCHEMBL7162480 0.72 GRIN2D (0.46)
SCHEMBL6830524 0.66 ALOX5 (0.30)
SCHEMBL4248928 0.64 DDB1 (0.35) DDB1CRBN
SCHEMBL12710695 0.64 GRIN2D (0.32)
SCHEMBL9951769 0.63 ALDH1A1 (0.36)
SCHEMBL28104 0.62 GRIN2D (0.55)
SCHEMBL4541131 0.62 ALDH1A1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists PFIZER INC. 2002-09-12 US claimed
US-6734306-B2 USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE PFIZER, INC. 2004-05-11 US disclosed
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists PFIZER INC. 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists BDKRB1, HRH2, BDKRB2 DDB1 1774/4885CRBN 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.